Xtant Medical Announces NYSE American Acceptance of Plan to Regain Compliance with Continued Listing Standards BELGRADE, MT

Medical Announces NYSE American Acceptance of Plan to Regain Compliance with Continued Listing Standards

MT, May 28, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on

surgical solutions for the treatment of spinal disorders, today announced that NYSE Regulation has accepted the

Company's plan to regain compliance with the NYSE American continued listing standards relating to stockholders'

equity. Xtant Medical submitted its plan on May 3, 2019, and has been granted a plan period through October 4,

listing of the Company's common stock will continue pursuant to an extension during the plan period, during which time the

Company will be subject to periodic review to determine whether it is making progress consistent with the accepted plan. Failure

to make progress consistent with the plan or to regain compliance with the continued listing standards by October 4, 2020 could

result in the Company's shares of common stock being delisted from the NYSE American.

Xtant Medical Holdings, Inc.

Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization

of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity

and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

symbols and denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered

as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are

the property of their respective owners.

Cautions Regarding Forward-Looking Statements

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions,

or that include words such as expects,'' anticipates,'' intends,''

plans,'' believes,'' estimates,'' "continue,"

"future," will,'' "potential" similar expressions or the negative thereof, and

the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties,

and actual results may differ materially depending on a variety of important factors, including, among others: the Company's

ability to make progress consistent with its plan of compliance and regain compliance with the continued listing standards of

the NYSE American; the Company's future operating results and financial performance; the ability to increase or maintain

revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of recent management

changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company

products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product

liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and

results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate

without infringing the rights of others; the ability to service Company debt and comply with debt covenants; the ability to raise

additional financing and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K

for the year ended December 31, 2018 filed with the Securities and Exchange Commission (SEC) on April 1, 2019 and subsequent SEC

filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended March

31, 2019 filed with the SEC on May 15, 2019. Investors are encouraged to read the Company's filings with the SEC, available

at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly

any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence

of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting

on its behalf are expressly qualified in their entirety by this cautionary statement.